Adverum Biotechnologies, Inc. (ADVM)

NASDAQ: ADVM · Real-Time Price · USD
4.610
-0.350 (-7.06%)
At close: Mar 28, 2025, 4:00 PM
4.840
+0.230 (4.99%)
After-hours: Mar 28, 2025, 5:09 PM EDT
-7.06%
Market Cap 95.90M
Revenue (ttm) 1,000,000
Net Income (ttm) -94.11M
Shares Out 20.80M
EPS (ttm) -5.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 124,017
Open 5.050
Previous Close 4.960
Day's Range 4.570 - 5.120
52-Week Range 3.520 - 14.210
Beta 1.13
Analysts Strong Buy
Price Target 27.83 (+503.69%)
Earnings Date May 8, 2025

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 121
Stock Exchange NASDAQ
Ticker Symbol ADVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ADVM stock is "Strong Buy." The 12-month stock price forecast is $27.83, which is an increase of 503.69% from the latest price.

Price Target
$27.83
(503.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly ...

27 days ago - GlobeNewsWire

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement ...

4 weeks ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p...

4 weeks ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p...

7 weeks ago - GlobeNewsWire

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directo...

4 months ago - GlobeNewsWire

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS...

4 months ago - Seeking Alpha

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a.m. EST

4 months ago - GlobeNewsWire

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

- 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H...

5 months ago - GlobeNewsWire

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular...

5 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly ...

7 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p...

8 months ago - GlobeNewsWire

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call July 17, 2024 8:00 AM ET Company Participants Mike Zanoni - Head of IR Laurent Fischer - Pre...

9 months ago - Seeking Alpha

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

-   6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks

9 months ago - GlobeNewsWire

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden

11 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly pr...

11 months ago - GlobeNewsWire

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly ...

1 year ago - GlobeNewsWire

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD -

1 year ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p...

1 year ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

1 year ago - GlobeNewsWire

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic...

1 year ago - GlobeNewsWire

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capit...

1 year ago - GlobeNewsWire

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsor...

1 year ago - GlobeNewsWire

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

1 year ago - GlobeNewsWire

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

1 year ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

1 year ago - GlobeNewsWire